Mark Fishman is an American cardiologist, a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the MGH for patients with complex medical disorders.[1] A researcher and clinician in cardiology, he is the previous president of the Novartis Institutes for BioMedical Research (NIBR),[2] the main research arm of Novartis Pharmaceuticals.[3]
Fishman was appointed president of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort.[4] He is the author of over 100 publications[5] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.[6][7][8]
He was previously a professor of medicine at Harvard Medical School, chief of cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine.[9]
After being the head of Novartis for 13 years, he decided to retire in 2016[10] and became professor at Harvard and Chief at MGH[1]
References
^ ab"Mark C. Fishman, M.D." Harvard Department Of Stem Cell And Regenerative Biology. Retrieved Oct 19, 2022.
^. Archived from the original on 2015-06-01. Retrieved 2009-10-20.
^. Archived from the original on 2011-02-02. Retrieved 2009-10-20.
^. Archived from the original on 2011-06-16. Retrieved 2009-10-20.
^Barut, Bruce A.; Zon, Leonard I. (2000). "Realizing the potential of zebrafish as a model for human disease". Physiological Genomics. 2 (2): 49–51. doi:10.1152/physiolgenomics.2000.2.2.49. PMID 11015581. S2CID 12510521.
^. Jan 2002. Archived from the original on 2009-04-03.
^(PDF). Archived from the original (PDF) on 2011-07-25. Retrieved 2009-10-20.
^Damian Garde (24 September 2015). "Novartis' top scientist is stepping down after 13 years, making way for a Harvard luminary". Fierce Biotech. Retrieved 13 December 2016.
External links
Novartis Institutes for BioMedical Research Official Homepage
Novartis Institutes for BioMedical Research Official Homepage
Mark Fishman on changing the grammar of drug discovery
January 07, 2023
mark, fishman, american, cardiologist, professor, harvard, department, stem, cell, regenerative, biology, chief, pathways, clinical, service, service, patients, with, complex, medical, disorders, researcher, clinician, cardiology, previous, president, novartis. Mark Fishman is an American cardiologist a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the MGH for patients with complex medical disorders 1 A researcher and clinician in cardiology he is the previous president of the Novartis Institutes for BioMedical Research NIBR 2 the main research arm of Novartis Pharmaceuticals 3 Mark FishmanCitizenshipUnited StatesAlma materYale College Harvard Medical SchoolKnown forpioneering Zebrafish research in cardiologyAwardsInstitute of Medicine member Fellow of the American Academy of Arts and SciencesScientific careerFieldsMedicine CardiologyInstitutionsNovartis Institutes of BioMedical Research Massachusetts General Hospital Harvard Medical SchoolFishman was appointed president of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis global drug discovery effort 4 He is the author of over 100 publications 5 and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease 6 7 8 Contents 1 Education 2 Career 3 References 4 External linksEducation EditB A Yale College 1972 M D Harvard Medical School 1976Career EditHe was previously a professor of medicine at Harvard Medical School chief of cardiology at Massachusetts General Hospital and director of the Cardiovascular Research Center at Massachusetts General Hospital He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences Institute of Medicine 9 After being the head of Novartis for 13 years he decided to retire in 2016 10 and became professor at Harvard and Chief at MGH 1 References Edit a b Mark C Fishman M D Harvard Department Of Stem Cell And Regenerative Biology Retrieved Oct 19 2022 Novartis People Archived from the original on 2015 06 01 Retrieved 2009 10 20 Novartis Corporate Fact Sheet Archived from the original on 2011 02 02 Retrieved 2009 10 20 PRdomain com Novartis Novartis steps up US research investment opening Cambridge Massachusetts Biomedical Research Center Archived from the original on 2011 06 16 Retrieved 2009 10 20 http www pubmed gov 183 results as of 20 Oct 2009 Barut Bruce A Zon Leonard I 2000 Realizing the potential of zebrafish as a model for human disease Physiological Genomics 2 2 49 51 doi 10 1152 physiolgenomics 2000 2 2 49 PMID 11015581 S2CID 12510521 Fishman profile Forbes com Jan 2002 Archived from the original on 2009 04 03 Fishman biographical sketch PDF Archived from the original PDF on 2011 07 25 Retrieved 2009 10 20 Media PDF Damian Garde 24 September 2015 Novartis top scientist is stepping down after 13 years making way for a Harvard luminary Fierce Biotech Retrieved 13 December 2016 External links EditNovartis Institutes for BioMedical Research Official Homepage Novartis Institutes for BioMedical Research Official Homepage Mark Fishman on changing the grammar of drug discovery Retrieved from https en wikipedia org w index php title Mark Fishman amp oldid 1119816791, wikipedia, wiki, book, books, library,
